Rosiglitazone and the FDA

N Engl J Med. 2007 Oct 25;357(17):1775-6; author reply 1777. doi: 10.1056/NEJMc076347. Epub 2007 Aug 29.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Advisory Committees
  • Cardiovascular Diseases / chemically induced*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Drug Approval*
  • Glycated Hemoglobin
  • Humans
  • Hypoglycemic Agents / adverse effects*
  • Rosiglitazone
  • Thiazolidinediones / adverse effects*
  • United States
  • United States Food and Drug Administration

Substances

  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • Thiazolidinediones
  • Rosiglitazone